BRIDGEBIO PHARMA INC (BBIO) Stock Earnings & Estimates
NASDAQ:BBIO - US10806X1028 - Common Stock
49.08 USD
-1.15 (-2.29%)
48.9 USD
-0.18 (-0.37%)
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 77.65M 11.37% | 9.303M -88.02% | 221.902M 2,285.27% | 478.17M 115.49% | 787.1M 64.61% | 1.317B 67.32% | 2.087B 58.47% | 2.735B 31.05% | 3.318B 21.32% | 3.738B 12.66% | 4.234B 13.27% | |
| EBITDA YoY % growth | -461.66M 19.12% | -592.95M -28.44% | -571.293M 3.65% | -402.203M 29.60% | -290.489M 27.78% | 118.48M 140.79% | -224.4M -289.40% | 71.4M 131.82% | 376.38M 427.14% | 709.92M 88.62% | 990.42M 39.51% | |
| EBIT YoY % growth | -468.43M 18.76% | -599.444M -27.97% | -577.368M 3.68% | -469.06M 18.76% | -338.576M 27.82% | 110.07M 132.51% | 577.14M 424.34% | 1.133B 96.31% | 1.546B 36.45% | 1.822B 17.85% | 2.249B 23.44% | |
| Operating Margin | -603.26% | -6,443.56% | -260.19% | -98.09% | -43.02% | 8.36% | 27.65% | 41.43% | 46.59% | 48.74% | 53.12% | |
| EPS YoY % growth | -3.11 20.46% | -3.94 -26.69% | -3.09 21.57% | -3.43 -11.02% | -2.18 36.37% | -0.39 82.05% | 1.87 578.21% | 4.33 131.03% | 5.92 36.76% | 7.69 29.93% | 9.24 20.12% |
All data in USD
| Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.91 16.97% | -0.84 40.11% | -0.76 13.79% | -0.64 32.22% | -0.57 37.78% | -0.48 43.03% |
| Revenue Q2Q % growth | 112.77M 4,027.75% | 130.47M 2,118.12% | 142.76M 22.40% | 168.82M 52.69% | 191.1M 69.46% | 234.88M 80.03% |
| EBITDA Q2Q % growth | -81.938M 55.08% | -51.679M 75.99% | -119.789M -16.85% | N/A | N/A | N/A |
| EBIT Q2Q % growth | -142.468M 23.87% | -123.945M 44.00% | -121.294M -16.85% | -97.738M 26.77% | -83.283M 41.54% | -41.548M 66.48% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | -0.95 -143.59% | -0.86 | -0.09 | -10.44% |
| Q1 2025 Q2Q % growth | -0.88 -340.00% | -0.94 | 0.06 | 6.56% |
| Q4 2024 Q2Q % growth | -1.40 -45.83% | -1.15 | -0.25 | -21.38% |
| Q3 2024 Q2Q % growth | -1.10 -1.85% | -1.00 | -0.10 | -10.20% |
| Q2 2024 Q2Q % growth | -0.39 60.20% | -1.09 | 0.70 | 64.07% |
| Q1 2024 Q2Q % growth | -0.20 78.26% | -0.78 | 0.58 | 74.34% |
| Q4 2023 Q2Q % growth | -0.96 -4.35% | -0.93 | -0.03 | -3.37% |
| Q3 2023 Q2Q % growth | -1.08 -16.13% | -0.83 | -0.25 | -29.83% |
| Q2 2023 Q2Q % growth | -0.98 -1,300.00% | -0.85 | -0.13 | -15.29% |
| Q1 2023 Q2Q % growth | -0.92 22.69% | -0.85 | -0.07 | -8.52% |
| Q4 2022 Q2Q % growth | -0.92 8.91% | -0.87 | -0.05 | -5.84% |
| Q3 2022 Q2Q % growth | -0.93 12.26% | -1.01 | 0.08 | 8.30% |
| Q2 2022 Q2Q % growth | -0.07 89.39% | -0.64 | 0.57 | 89.13% |
| Q1 2022 Q2Q % growth | -1.19 -0.85% | -1.13 | -0.06 | -5.11% |
| Q4 2021 Q2Q % growth | -1.01 | -0.89 | -0.12 | -14.11% |
| Q3 2021 Q2Q % growth | -1.06 -8.16% | -0.92 | -0.14 | -15.33% |
| Q2 2021 Q2Q % growth | -0.66 35.92% | -0.96 | 0.30 | 31.27% |
| Q1 2021 Q2Q % growth | -1.18 -51.28% | -0.75 | -0.43 | -56.60% |
| Q4 2020 Q2Q % growth | -1.01 -62.90% | -0.87 | -0.14 | -16.65% |
| Q3 2020 Q2Q % growth | -0.98 -92.16% | -0.94 | -0.04 | -4.43% |
| Q2 2020 Q2Q % growth | -1.03 70.23% | -0.79 | -0.24 | -30.80% |
| Q1 2020 Q2Q % growth | -0.78 | -0.68 | -0.10 | -13.89% |
| Q4 2019 Q2Q % growth | -0.62 | -0.71 | 0.09 | 12.81% |
| Q3 2019 Q2Q % growth | -0.51 | -0.56 | 0.05 | 9.37% |
| Q2 2019 Q2Q % growth | -3.46 | -0.53 | -2.93 | -557.76% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q2 2025 Q2Q % growth | 110.565M 4,999.86% | 93.238M | 17.327M | 18.58% |
| Q1 2025 Q2Q % growth | 116.633M -44.76% | 63.179M | 53.454M | 84.61% |
| Q4 2024 Q2Q % growth | 5.882M 237.08% | 3.549M | 2.333M | 65.74% |
| Q3 2024 Q2Q % growth | 2.732M -33.22% | 3.837M | -1.105M | -28.80% |
| Q2 2024 Q2Q % growth | 2.168M 32.11% | 3.641M | -1.473M | -40.46% |
| Q1 2024 Q2Q % growth | 211.12M 11,461.88% | 14.314M | 196.806M | 1,374.92% |
| Q4 2023 Q2Q % growth | 1.745M -6.68% | 6.353M | -4.608M | -72.53% |
| Q3 2023 Q2Q % growth | 4.091M 1,103.24% | 4.118M | -27K | -0.66% |
| Q2 2023 Q2Q % growth | 1.641M -97.77% | 3.053M | -1.412M | -46.25% |
| Q1 2023 Q2Q % growth | 1.826M 8.05% | 3.443M | -1.617M | -46.96% |
| Q4 2022 Q2Q % growth | 1.87M -85.49% | 4.615M | -2.745M | -59.48% |
| Q3 2022 Q2Q % growth | 340K -85.47% | 8.063M | -7.723M | -95.78% |
| Q2 2022 Q2Q % growth | 73.75M 36.52% | 16.389M | 57.361M | 350.00% |
| Q1 2022 Q2Q % growth | 1.69M 267.39% | 4.789M | -3.099M | -64.71% |
| Q4 2021 Q2Q % growth | 12.89M 10,641.67% | 22.009M | -9.119M | -41.43% |
| Q3 2021 Q2Q % growth | 2.34M -71.22% | 17.706M | -15.366M | -86.78% |
| Q2 2021 Q2Q % growth | 54.02M | 35.536M | 18.484M | 52.01% |
| Q1 2021 Q2Q % growth | 460K | 31.091M | -30.631M | -98.52% |
| Q4 2020 Q2Q % growth | 120K -99.13% | 17.269M | -17.149M | -99.31% |
| Q3 2020 Q2Q % growth | 8.13M -69.60% | 8.772M | -642K | -7.32% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -0.45% | 13.25% | 0% | 0.46% |
| Revenue | 19.1% | 129.12% | -0.49% | 9.11% |